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Abstract
Background: Allergy to cat epithelia is highly prevalent, being the major recommendation for allergy sufferers its
avoidance. However, this is not always feasible. Allergen specific immunotherapy is therefore recommended for
these patients. The use of polymerized allergen extracts, allergoids, would allow to achieve the high allergen doses
suggested to be effective while maintaining safety.
Results: Cat native extract and its depigmented allergoid were manufactured and biochemically and
immunochemically characterized. Protein and chromatographic profiles showed significant modification of the
depigmented allergoid with respect to its corresponding native extract. However, the presence of different
allergens (Fel d 1, Fel d 2, Fel d 3, Fel d 4 and Fel d 7) was confirmed in the allergoid. Differences in IgE-binding
capacity were observed as loss of biological potency and lower stability of the IgE-allergen complex on surface
plasmon resonance. The allergoid induced production of IgG antibodies able to block IgE-binding to native extract.
Finally, studies carried out with peripheral-blood mononuclear cells from cat allergic patients showed that the
allergoid induced IFN-γ and IL-10 production similar to that induced by native extract.
Conclusions: Cat depigmented allergoid induced production of cytokines involved in a Th1 and Treg response,
was able to induce production of IgG-antibodies that blocks IgE-binding to cat native extract, and showed reduced
interaction with IgE, suggesting greater safety than native extract while maintaining in vitro efficacy.
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Background
Sensitization to cat dander presents a high prevalence,
affecting more than 25% of the population in Western
countries [1] and more than 15% in the US [2]. Around
half of sensitized patients may present symptoms [3],
being rhinoconjunctivitis the most frequent symptom.
Apart from avoidance strategies or symptomatic treat-
ment, cat allergy is currently treated with immunotherapy
consisting of the administration of native extracts (NE)
either via subcutaneous or sublingual routes of adminis-
tration. The use of cat native extracts has demonstrated
clinical efficacy and safety profile in several clinical trials
[4, 5], being the efficacy related to Fel d 1 content [6], and
the amount of extract used is in turn related to adverse
reactions [7]. The development of chemically modified
allergen extracts by polymerization with glutaraldehyde
has been postulated as an alternative in immunotherapy,
maintaining/increasing the efficacy while reducing the risk
of adverse reactions [8]. The resulting products are high
molecular weight allergen chains which contain all the
allergens present in NE in a polymerized form. An inter-
mediate patented process known as “depigmentation” [9]
consist on the purification of the NE for the removal of
irrelevant allergenic substances with the objective to
increase the concentration of the individual allergens. To
date, this method has yielded good results in other aeroal-
lergens, including mites and pollens [10, 11]. Other alter-
natives based on immunologically active peptides are
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currently under investigation [12, 13]. In addition, mono-
meric carbamylated allergoid sublingual immunotherapy
also present good results [14].
In recent years, different techniques have been imple-
mented in characterization of active substances used in
immunotherapy, providing a clear advantage not only in
the quality of immunotherapy treatments already in the
market but also supporting and providing useful infor-
mation for immunotherapeutic design and for the early
stages of the development process. Measurement of IgE
interaction with allergens by surface plasmon resonance
(SPR) analysis has been postulated as an indicator of
safety [15], while cellular assays based on cytokine
release or quantification of IgE-blocking IgG-antibodies
indicate immunological response suggesting efficacy.
The design of immunotherapy based on immunological
principles seems logical to guarantee the success of new
products.
Based on these concepts, the objective of this study
was to design and produce a depigmented allergoid of
cat epithelium to be used in immunotherapy based on
safety and efficacy data.
Methods
Allergen extract preparation
Two hundred grams of cat dander (Allergon, Sweden)
were extracted in Phosphate Buffered Saline 0.01 M under
continuous magnetic stirring, for 4 h at 4 °C. The resulting
product was called native extract (NE). The NE was depig-
mented after a mild acid treatment (pH 2) followed by dia-
lysis against bi-distilled water with a cut-off membrane of
3.5 kDa (Cellu Sep Membrane, Seguin, TX, USA) with the
objective to remove the low molecular weight compo-
nents. Finally the pH was adjusted to seven. The resulting
depigmented extract was polymerized with glutaraldehyde
at a concentration of 5 mg/ml and extensively dialyzed
against bi-distilled water in 100 kDa dialysis membranes
(Millipore, Bedford, USA) to remove non-polymerized
compounds. Finally, the polymerized product was freeze-
dried, obtaining the cat depigmented-polymerized extract
(CDA). All extracts were manufactured in strict compli-
ance with GMP principles, following internal procedures
(Laboratorios LETI, Spain, [9]).
Serum samples and PBMC
A pool of four sera was used to evaluate IgE-binding to
allergen extracts. In that sense, sera from cat-sensitized
individuals were purchased from Plasmalab International
(WA, USA), which operates in full compliance with U.S.
Food and Drug Administration regulations. Specific IgE
titer to cat dander in the pool of sera were 66.4 KU/l, to
Fel d 1 55.3 KU/l, to Fel d 2 6.43KU/l, and to Fel d 4
9.60 KU/l, performed in ImmunoCAP system (Thermo
Fisher Scientific, MA USA). The pool of sera was
negative for bromelain (0.05 KU/l).
Polyclonal antibodies were used for IgG-binding assays
to allergen extracts. Specific antibodies were induced in
two New Zealand white rabbits after three immuniza-
tions with 200 μg of CDA adsorbed onto 3% aluminium
hydroxide. All procedures were approved by the Biolab
Institutional Review Board (Biolab, S.L., Colmenar Viejo,
Spain), and followed local ethics rules for animal
experimentation.
Peripheral-blood mononuclear cell (PBMC) culture su-
pernatants (Sanguine BioSciences, CA, USA, compliant
with FDA regulations) from three asthmatic cat-atopic
donors not previously treated with immunotherapy were




The protein content of NE and CDA extracts was mea-
sured using the Lowry–Biuret method (Sigma Diagnostics,
St. Louis, USA) following the manufacturer’s instructions.
Protein profile
One hundred micrograms of NE and CDA extracts were
loaded in SDS–PAGE gels with 2.67% C, 15% T acryl-
amide under reducing conditions and stained with Biosafe
Coomassie (Bio-Rad Laboratories, Hercules, CA, USA).
Allergenic profile
Proteins from previously prepared SDS–PAGE gels (see
above) were transferred to an Immobilon®-P membrane
(Millipore, Bedford, Mass., USA). Thereafter, the mem-
brane was incubated overnight with a pool of sera from
cat-sensitized individuals. Afterwards, the membrane was
washed and finally incubated with monoclonal α-human-
IgE-PO (Ingenasa, Madrid, Spain). Finally the reaction
was developed with Immun-Star™ Western Kit (BioRad).
Fel d 1, the major allergen from cat, was identified
using a similar methodology but using as a primary
antibody α-Fel d 1 monoclonal antibody-biotin (Indoor
Biotech, VA, USA). After washing, the membrane was
incubated with streptavidin-peroxidase and finally devel-
oped with Immun-Star™ Western Kit.
Major allergen quantification
Major allergen, Fel d 1, was quantified in NE extract using
a specific commercial kit (EL-FD1) following manufac-
turer´s instructions (Indoor Biotech, VA, USA). Data were
adjusted to a four-parameter logistic curve by the least-
squares method. Determination of Fel d 1 in CDA was
estimated based on NE determination and yield.
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Polymerization profile
CDA molecular weight distribution was determined by
SDS-PAGE (AnyKD TGX Precast Gels, BioRad Labora-
tories, CA, USA) using a high-molecular weight stand-
ard (Thermo Fisher Scientific Inc, MA USA), and by
high-performance size exclusion chromatography (SEC)
using a Bio SEC-3 Column (Agilent Technologies, CA,
USA) in a 1200 series HPLC system (Agilent), at 1 ml/
min 150 mM phosphate buffer, pH 7. Detection was
performed at UV-280 nm.
Allergen identification
The presence of relevant allergens in NE and CDA was
determined by mass spectrometry. Briefly, extracts were
digested with trypsin and the peptide mixture was ana-
lyzed in a nanoAcquity liquid chromatography system
(Waters Corporation, MA, USA) coupled to a LTQ-
Orbitrap Velos (Thermo) mass spectrometer. Raw data
were collected with ThermoXcalibur software (Thermo).
A database search was performed through the Mascot
search engine using Thermo Proteome Discover against
the Uniprot database.
In vitro safety
IgE affinity by Surface Plasmon Resonance SPR mea-
surements were performed on a Biacore T100 system
(Biacore, Uppsala, Sweden). Briefly, α-human-IgE was
immobilized through amine coupling onto a C1 chip
(GE Healthcare, NJ, USA) and the reference flow cell
was treated using the same chemicals but in the absence
of antibodies. The pool of sera from cat-sensitized indi-
viduals was diluted 1:2 and injected to capture IgE. Fi-
nally, NE and CDA (0.4 mg/ml) were injected to
determine the stability of the IgE-NE or IgE-CDA com-
plexes by measuring the dissociation rate (kd) and half-
life (t½ = ln2/kd) of the complex.
IgE binding capacity by determination of biological
potency Biological potency of the extracts was calcu-
lated by ELISA competition assays, as previously
described [16]. Briefly, each extract is compared with the
In House Reference Preparation (IHRP), previously in
vivo standardized. Nunc microplates (Thermo Scientific)
were coated with anti-IgE (Ingenasa, Madrid, Spain). A
pool of sera from cat sensitized patients was incubated
in the plate. Dilutions of the sample and IHRP were in-
cubated with the allergen labelled with peroxidase. The
mixture was added to the coated plate and incubated.
Afterwards, development solution (chromogen) was
added, stopped with sulfuric acid and measured at OD
450 nm. Percentage of loss of potency was calculated as
difference of biological potency between NE and CDA
divided by NE potency.
In vitro efficacy
IgE Blocking antibodies The capacity of CDA to in-
duce allergen-specific polyclonal IgG antibodies able to
block IgE binding sites to the allergen was evaluated by
ELISA inhibition, as previously described [17]. Briefly,
microplates were coated with NE (2 μg/well). After incu-
bation with the generated polyclonal antibodies against
CDA, plates were incubated with the pool of sera from
cat-sensitized individuals. A secondary antibody anti-
human-IgE-PO (Ingenasa, Madrid, Spain) was used for
detection at 405 nm. Percent of inhibition was calculated
by comparing IgE binding after incubation with preim-
mune or final bleeding polyclonal antibodies. Briefly,
CDA capacity to induce sIgG with capacity to inhibit IgE
binding of patients serum to a cat epithelia NE was eval-
uated. Percentage of inhibition was calculated as follows:
percentage of IgE binding = 100 − (ODf/OD P ) × 100.
ODf and ODP correspond to the optical densities after
the preincubation of serum with the rabbit’s final sera
and the corresponding preimmune sera, respectively.
Cytokine production The capacity to stimulate cytokine
production in PBMCs was evaluated using a quantitative
ELISA-based Q-Plex™ test (Quansys Biosciences, UT,
USA), performed in accordance with the manufacturer’s
instructions. PBMCs (2×105 cells per well) from cat sensi-
tized patients were stimulated in triplicate with NE or
CDA extract (100 μg/ml), and the production of IL-4,
IFN-γ, IL-10 and IL-17 cytokines was measured in culture
supernatants at 24 and 72 h. Phosphate buffered saline
(PBS, 50 ng/ml) and concanavalin A (Con A, 5 μg/ml)
were used as negative and positive controls, respectively.
Results
Protein and major allergen content
Protein content estimated by the Lowry-Biuret method
was 216 μg prot/mg in NE and 254 μg prot/mg in CDA.
NE contained approximately 25 μg of Fel d 1/mg. The
estimated Fel d 1 content in CDA was 48 μg/mg.
Protein and allergen profile
The protein profile of NE (Fig. 1a) showed different
bands of a wide range of molecular weight. The most
prominent bands showed a low molecular weight
(mainly 8 and 6 kDa). On the contrary, CDA showed
higher molecular weight bands.
Allergenic profile was significantly different between
NE and CDA (Fig. 1b), showing the most intense IgE-
recognized band at 18 kDa in NE, coincident with Fel d
1 heterodimer (constituted by two subunits, of 4 and
14 kDa). Fel d 1 can also be found in a 36 kDa tetramer
form. Fel d 1 band identity was confirmed by immuno-
blot using α-Fel d 1 monoclonal antibody (Fig. 1c). IgE
binding to Fel d 1 was not observed in CDA (Fig. 1b),
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and α-Fel d 1 monoclonal antibody recognition was less
intense (Fig. 1c).
Polymerization profile
Specific methods (SDS-PAGE and SEC-HPLC) for detec-
tion of high molecular weight proteins were used to evalu-
ate CDA polymerization profile (Figs. 1d and 2). Both
methods showed a significant modification of CDA pro-
tein profile with respect to its corresponding NE. Low mo-
lecular weight proteins (at 4 and 14 kDa) were observed
in NE but not in CDA (Fig. 1d. Proteins of approximately
31 and 107 kDa were observed in CDA chromatogram,
although a high percentage of molecules exhibited a
molecular weight higher than 1500 kDa (Fig. 2).
Allergen identification
NE was sequenced by mass spectrometry, which con-
firmed the presence of Fel d 1, Fel d 2, Fel d 3, Fel d 4
and Fel d 7. The sequence coverage was 59% for chain 1
Fel d 1 (compared to Uniprot sequence code P30438),
40% for chain 2 Fel d 1 (Uniprot P30440), 51% for Fel d
2 (Uniprot M3WFW6), 69% for Fel d 3 (Uniprot
Q8WNR9), for 37% Fel d 4 (Uniprot Q5VFH6) and 48%
for Fel d 7 (Uniprot E5D2Z5). CDA sequencing showed
the same allergens identified in NE.
CDA sequencing showed the same allergens identified
in NE. Sequences coverage were 59% for chain 1 Fel d 1
(compared to Uniprot sequence code P30438), 26% for
chain 2 Fel d 1 (Uniprot P30440), 45% for Fel d 2 (Uni-
prot P49064), 47% for Fel d 3 (Uniprot Q8WNR9), 29%
for Fel d 4 (Uniprot Q5VFH6) and 52% for Fel d 7
(Uniprot E5D2Z5).
In vitro safety
In vitro safety was evaluated as the reduced IgE binding
capacity of CDA compared to NE. Two assays were
planned. The first one was IgE binding to evaluate
dissociation constant and half-life of the complex IgE-
extract by Surface Plasmon Resonance. The second one
was the loss of biological potency after polymerization.
This was performed by ELISA competition assays com-
paring IgE binding capacity of NE and CDA to a IHRP.
The stability of the complex Antigen-IgE, measured by
SPR, showed that the kd of IgE-CDA was 8.0*10
−3s−1
and the t½ was 87.22 s. In contrast, the kd of IgE-NE was
1.9*10−3s−1, and the t½ was 360.2 s. The IgE-CDA com-
plex was 4.1 times less stable than IgE-NE regarding the
half life of the complex. In line with these results,
polymerization induced a loss of biological potency
higher than 95%. CDA presented a biological potency of
15 HEPL/mg, that represented a 99% of loss of biological
potency compared to the NE (1035 HEPL/mg).
In vitro efficacy
CDA extract induced the production of IgG antibodies
able to block up to IgE-binding sites. Specific IgE titers
serums showed a low titer of sIgG titer (consequence of
natural exposure to this allergen) lower than final bleed-
ing samples. There was a 90% increase of induced
inhibition comparing final and preimmune bleeding
polyclonal samples (Fig. 3).
Cellular studies showed a similar production of IFN-γ
and IL-10 (Fig. 4) by NE and CDA extracts. After 72 h,
NE induced levels of 258.1 pg IFN-γ/ml and 648.7 pg
IL-10/ml, while CDA induced 394.7 pg IFN-γ/ml and
520.7 pg IL-10/ml. IL-17 and IL-4 were not detected in
any case (values below the limit of quantification).
Discussion
Cat allergy is one of the most prevalent allergic diseases
in Western countries [1, 2]. Although limited clinical
studies and numerous clinical observations have
Fig. 1 SDS-PAGE (a) and immunoblot (b and c) of cat epithelia in
reducing conditions (15%T-2.67%C): Precision Plus Protein Dual Extra
Standard (lane 1), NE (100 μg extract, lane 2) and CDA (100 μg, lane 3).
Immunoblots were performed using serum from cat sensitized
patients (b) or monoclonal antibody α-Fel d 1 (c) as primary antibody.
High molecular weight SDS (d): HiMarkTM Pre-Stained HMW Protein
Standard (lane 1), CDA (100 μg extract, lane 2), and NE (100 μg, lane 3)
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demonstrated the efficacy of cat immunotherapy with
native extracts [4–6, 18], the adverse reactions associ-
ated to these allergenic extracts remains being an issue
to be solved. To our knowledge, this is the first time that
a polymerized allergenic extract is manufactured and its
safety and efficacy deeply evaluated by in vitro tech-
niques. The manufacturing process was designed based
of the reduction of the IgE binding capacity, but also to
increase the immunological and clinical efficacy of the
product by confirming the presence of the relevant aller-
gens and the stimulation of the appropriate immuno-
logical pathways. The present study confirmed that CDA
was immunologically active and able to induce a Th1/
Treg response. Moreover, it also induced the production
of IgG blocking antibodies, inhibiting the IgE binding
capacity of serum obtained from allergic patients. In
addition, CDA was also less allergenic, as its binding
capacity to IgE was lower than that of NE.
In recent years, many studies have tried to elucidate
the mechanism of action of immunotherapy. It has been
suggested that successful allergen immunotherapy
should be accompanied by induction of regulatory T
cells (Treg) and shift from a Th2 response toward a Th1
response [19]. Additionally, recent studies have sug-
gested that specific biomarkers for measurement of the
success of immunotherapy should be related to the cap-
acity of allergen vaccines to specifically stimulate pro-
duction of IL-10 and IFN-γ, which are involved in the
Th1 and Treg responses, respectively, and a reduction of
IL-4 [20]. In our case, CDA stimulated the release of IL-
10 and IFN-γ, suggesting a beneficial immune response
that could lead to tolerance. On the contrary, IL-4 was
not detected after either treatment, nor with positive
control.
The clinical efficacy of immunotherapy has been also
associated with the ability of the immunotherapeutic agent
Fig. 3 ELISA inhibition assay. Plates were coated with NE and incubated with polyclonal antibodies before human serum was added. Specific IgE
binding to the plate was detected using anti-human-IgE-PO. Left: inhibition of preimmune and final bleeding serum samples. Right: inhibition of
final bleeding compared to preimmune serum samples
Fig. 2 Size exclusion chromatogram: NE (blue line) and CDA (red line) detected at 280 nm (elution time in minutes). Optical density of NE is
marked in left y-axe, and CDA in right y-axe
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to induce IgG antibodies that block IgE-binding sites to the
allergens (humoral response) [21]. The results obtained
with CDA were positive. CDA extract administered in
rabbits produced specific antibodies with capacity to block
the IgE binding sites of NE epitopes. This is consistent with
the detection of relevant allergens in CDA by mass
spectrometry [22]. This means that CDA is captured and
processed by the cells of the immune system, producing a
specific response (specific IgG) against the allergens
combined in the polymerized chains. These specific IgG
antibodies generated after the administration of CDA are
recognizing and block the natural allergens to which
patients are exposed when they are in contact with the
allergenic source, in this case, cats. In consequence, the
treatment with CDA induces sIgG that blocks IgE binding
to the allergen in patients serum [14].
On the other hand, adverse reactions and anaphylaxis as
a consequence of IgE reactions remain as the major threat
of immunotherapy. Several approaches have been used to
reduce immunotherapy-induced side effects. These in-
clude immunotherapy with hypoallergens, T-cell epitope-
containing peptides, and formulations consisting of Fel d
1 coupled to an immunomodulatory protein or carrier
[23]. The polymerization process is the most common
method for the reduction of allergenicity because it re-
duces IgE reactivity, thus improving treatment safety [11].
In our case, the CDA showed a different chromatographic
profile compared to NE, characterized by proteins with
higher molecular weight. Polymerization also induced a
loss of IgE binding, as observed on immunoblot assays,
and loss of potency of the CDA extract compared to its
corresponding NE, used as a marker of safety. In recent
years, new methods based on measurement of the kinetic
reaction between antigen and antibody have been postu-
lated as a reliable alternative for the determination of the
safety prior to in vivo assays [15]. CDA extract showed
more than 4 times less affinity to IgE than NE confirming
that the polymerized extract is safer for immunotherapy
than native extracts using the same amount of material.
Conclusions
In summary, we have produced a depigmented and poly-
merized allergen extract of cat dander to be used as an
alternative for cat allergy treatment. The new extract has
been designed based on immunological efficacy and safety
parameters. The results obtained demonstrate that CDA
induces the production of cytokines involved in a Th1 and
Treg response (induction of tolerance), is able to induce
the production of IgG-blocking antibodies (humoral
response), and exhibits reduced interaction with IgE, con-
firming in vitro efficacy and higher safety than NE. Further
in vivo studies should be performed on allergic patients to
prove the safety and efficacy of this extract, but the
present results suggest that it is a good candidate for the
treatment of allergy to cats. New in vitro methods and
biomarkers should be optimized in order to design better
products for treatments. This work shows the steps
followed to evaluate efficacy and safety in vitro during the
development of a cat allergoid, which would decrease risks
in future clinical trials.
Fig. 4 Mean value of the IFN-γ (left) and IL-10 (right) induction (in pg/ml) by PBMCs from cat-allergic donors (N = 3) after 24 or 72 h of treatment
with PBS (negative control), concanavalin A (positive control), cat depigmented allergoid (CDA) or native cat extracts (NE). Error bars refer to
standard deviation
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